TICKERNERD
Menu
ALMSALMSHealthcare · Biotechnology

ALMS Stock Forecast: Alumis, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$6.97
+2.95% on the day

The 10 Wall Street analysts covering Alumis, Inc. hold a median 12-month price target of $32 — +359.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$876.3M
Ticker Nerd rank
42 / 100
Median analyst target
$32
Analysts covering
10
Revenue$1.7M−37.7% y/y
Operating income−$107.0M
Net income−$142.2M
Free cash flow−$81.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.3%
1M
−34.1%
YTD
−28.6%
1Y
+57.3%
From 52W high
−77.0%
From 52W low
+57.3%
$4
$30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALMS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alumis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
42 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
81
Growth
78
Momentum
64
Size
45
Volatility
44
Issuance
40
Value
34
Revisions
30
Quality
29

Accruals (81): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (29): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALMS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALMS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50Jan 26Apr 26Jul 26Oct 26ALMSHigh $46Median $32Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $15Median $32High $46

The green dot is the last close — the median target sits +359.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
3 Sept 2026GuggenheimDowngradeNeutral—
2 Sept 2026HC Wainwright & Co.UpgradeBuy$25 → $15
2 Sept 2026Morgan StanleyMaintainsOverweight$39 → $29
2 Sept 2026OppenheimerMaintainsOutperform$55 → $37
2 Sept 2026Wells FargoMaintainsOverweight$51 → $25
14 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
14 Aug 2026HC Wainwright & Co.ReiteratesNeutral$25
3 Aug 2026HC Wainwright & Co.ReiteratesNeutral$25
3 Aug 2026HC Wainwright & Co.ReiteratesNeutral—
19 May 2026Chardan CapitalMaintainsBuy$38 → $40
19 May 2026Chardan CapitalMaintainsBuy—
15 May 2026GuggenheimMaintainsBuy$32 → $34
15 May 2026GuggenheimMaintainsBuy—
15 May 2026HC Wainwright & Co.DowngradeNeutral$25
15 May 2026HC Wainwright & Co.DowngradeNeutral—
15 May 2026Wells FargoMaintainsOverweight—
15 May 2026Wells FargoMaintainsOverweight$49 → $51
30 Mar 2026Chardan CapitalMaintainsBuy—
30 Mar 2026HC Wainwright & Co.MaintainsBuy—
30 Mar 2026OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALMS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALMS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Alumis, Inc. returned +57.3% against +16.2% for the S&P 500, dividends included.

ALMS vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600700Jan 26Apr 26Jul 26Oct 26ALMSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALMS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
3
Fundamentals

Alumis, Inc. (ALMS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 73% of US stocks

Price / sales
118.4×

Cheaper than 4% of US stocks

Price / book
1.9×

Cheaper than 45% of US stocks

EV / EBITDA
−1.0×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
−37.7%

Higher than 7% of US stocks

Earnings growth (YoY)
−37.7%

Higher than 14% of US stocks

Gross margin
—
Operating margin
−6439.9%

Higher than 2% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−93.6%

Higher than 14% of US stocks

Return on assets
−45.3%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alumis, Inc. (ALMS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alumis, Inc. has a market value of $876.3M and an enterprise value of $431.1M.

  • Revenue in the twelve months to 30 June 2026: $7.4M. The latest quarter shrank 37.7% year on year.

  • Net income over the same four quarters: −$439.0M, a −5933.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$351.8M.

  • Shares outstanding: 128.5M.

  • Trailing P/E: 0.2×; forward P/E: −2.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Alumis, Inc. employs 237 people — $31K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ALMS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALMSAlumis, Inc.$876.3M
42
JBIOJade Biosciences, Inc.$899.9M
26
MLTXMoonLake Immunotherapeutics$900.4M
16
RIGLRigel Pharmaceuticals, Inc.$901.4M
81
GLUEMonte Rosa Therapeutics, Inc.$871.8M
63
TBPHTheravance Biopharma, Inc.$857.7M
—
CRVSCorvus Pharmaceuticals, Inc.$855.3M
54

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alumis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALMS news & analysis

Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

GlobeNewsWire · 9 Oct 2026positive

Alumis reported new Phase 3 ONWARD program data for envudeucitinib, describing rapid and durable improvements in psoriasis burden across scalp, itch, and quality-of-life measures. The company said patients switching from placebo or apremilast achieved rapid responses comparable to continuous-treatment patients at Week 48, and reiterated that it is on track to submit an NDA in 4Q 2026.

Why it matters — The results add to the clinical evidence for envudeucitinib as Alumis advances toward a planned NDA submission for moderate-to-severe plaque psoriasis.

Alumis Inc. (ALMS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 14 Sept 2026neutral

Alumis Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The event featured the company's participation in the industry conference.

Why it matters — The presentation offers Alumis watchers insight into the company's corporate message and positioning as shared with the investment community at a major healthcare conference.

Alumis to Participate in Upcoming September Investor Conferences

GlobeNewsWire · 4 Sept 2026neutral

Alumis Inc., a late-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases, announced on September 4, 2026, that it will participate in upcoming investor conferences in September.

Why it matters — Investors watching ALMS may gain insight into the company's progress and strategy through its presentations at upcoming investor conferences.

Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside

Seeking Alpha · 1 Sept 2026negative

Seeking Alpha reports that Alumis Inc. is a late-stage biotech with no commercial product whose value rests primarily on envudeucitinib, a selective TYK2 inhibitor for psoriasis and lupus. A recent lupus trial failure caused a significant share price crash, though the report suggests this may not erase the drug's psoriasis potential.

Why it matters — ALMS watchers would care because the lupus trial failure is a major setback to the company's primary pipeline asset, although its psoriasis program may still support some upside.

A Lupus Drug Was a Failure and This Biotech Stock Is Down 58% Because of It

Barrons · 1 Sept 2026negative

Alumis, Inc. shares fell after the California-based biotech reported that envudeucitinib failed to meet the primary endpoint of a mid-stage lupus trial. The drug's failure in this trial drove a 58% decline in the company's stock.

Why it matters — The failure of envudeucitinib in a mid-stage lupus trial raises significant questions about the prospects of one of Alumis's key pipeline candidates.

FAQ

Frequently asked questions about ALMS stock

What is the ALMS stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Alumis, Inc. have a median 12-month price target of $32, with estimates ranging from $15 to $46. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALMS stock a buy right now?

Of the 10 analysts covering Alumis, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alumis, Inc. 42 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALMS?

As at 8 Oct 2026, Alumis, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (81 of 100).

Will ALMS stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +359.1% from the last close, and Ticker Nerd's factor model ranks Alumis, Inc. 42 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALMS stock forecast for 2030?

No analyst covering Alumis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALMS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $46 over the next 12 months.

How has ALMS stock performed over the past year?

Alumis, Inc. returned +57.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alumis, Inc. do?

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases.

What is the latest news on ALMS?

The most recent item we track (GlobeNewsWire, 9 Oct 2026): "Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures". Alumis reported new Phase 3 ONWARD program data for envudeucitinib, describing rapid and durable improvements in psoriasis burden across scalp, itch, and quality-of-life measures. The company said patients switching from placebo or apremilast achieved rapid responses comparable to continuous-treatment patients at Week 48, and reiterated that it is on track to submit an NDA in 4Q 2026.

Company

About Alumis, Inc.

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. The company’s current pipeline centers on oral TYK2 inhibitors designed to address conditions such as plaque psoriasis and systemic lupus erythematosus, alongside a CNS-penetrant TYK2 program being studied for neuroinflammatory and neurodegenerative disorders. Alumis is also advancing lonigutamab, an antibody therapy aimed at thyroid eye disease, and additional discovery-stage programs built around its precision data analytics platform. The company works across immunology and inflammation, combining drug discovery, clinical development, and translational science to build treatments that may be used as monotherapy or in combination settings. Headquartered in South San Francisco, California, Alumis operates as a focused biotech platform in the autoimmune and immune dysfunction market.

CEO Mr. Martin Babler Ph.D. · 237 employees · United States · https://www.alumis.com